NCT05406908View on ClinicalTrials.gov

Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

March 20, 2023

Study Completion Date

May 1, 2023

Conditions
Bullous DermatosesPsoriasisCOVID-19 Vaccines
Interventions
BIOLOGICAL

tozinameran

Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)

Trial Locations (1)

10400

Dermatology outpatient clinic, Somdech Phra Debaratana Medical Center, Ramathibodi Hospital, Mahidol University, Ratchathewi

All Listed Sponsors
lead

Mahidol University

OTHER